MD SEC-Einreichungen - Pediatrix Medical Group, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

CIK

893949

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pediatrix Medical Group, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 21, 2026	S-8	As filed with the Securities and Exchange Commission on May 21, 2026 As filed with the Securities and Exchange Commission on May 21, 2026 Registration No.
May 21, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Pediatrix Medical Group, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.01 par value Other 8,000,000 $ 23.02 $ 184,160,000.00 0.0001381 $ 25,432.50 Total Offe
May 7, 2026	8-K	FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.07 Submission of Matters to a Vote of Security Holders. Item 9.01 Financial S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2026 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 5, 2026	EX-99.1	Pediatrix Medical Group Reports First Quarter Results FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 [email protected] FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports First Quarter Results FORT LAUDERDALE, Fla., May 5, 2026 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three mo
May 5, 2026	EX-10.1	as Trustee GUARANTEED BY THE GUARANTORS, INCLUDING AS SET FORTH HEREIN NINTH SUPPLEMENTAL INDENTURE Dated as of March 31, 2026 to the Dated as of December 8, 2015 GUARANTEES OF 5.375% SENIOR NOTES DUE 2030 Exhibit 10.1 PEDIATRIX MEDICAL GROUP, INC. TO U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee GUARANTEED BY THE GUARANTORS, INCLUDING AS SET FORTH HEREIN NINTH SUPPLEMENTAL INDENTURE Dated as of March 31, 2026 to the INDENTURE Dated as of December 8, 2015 GUARANTEES OF 5.375% SENIOR NOTES DUE 2030 NINTH SUPPLEMENTAL INDENTURE 5.375% SENIOR NOTES DUE 2030 THIS NINTH SUPPLEMENTAL INDENTURE
May 5, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2026 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 5, 2026	10-Q	Consolidated Statements of Income and Comprehensive Income for the Three Months Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures PART II - OTHER INFORMATION Legal Proceedings Risk Factors SIGNATURES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gr
April 17, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 27, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 27, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 27, 2026	ARS	ARS 2025 ANNUAL REPORT ®Corporate Profile: Pediatrix ® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal
February 19, 2026	EX-19	PEDIATRIX MEDICAL GROUP, INC. POLICY STATEMENT ON INSIDE INFORMATION AND INSIDER TRADING FOR DIRECTORS, MANAGEMENT INSIDERS, FINANCIAL INSIDERS, SYSTEMS INSIDERS AND OTHER INSIDERS Revised February 17, 2026 Exhibit 19 PEDIATRIX MEDICAL GROUP, INC. POLICY STATEMENT ON INSIDE INFORMATION AND INSIDER TRADING FOR DIRECTORS, MANAGEMENT INSIDERS, FINANCIAL INSIDERS, SYSTEMS INSIDERS AND OTHER INSIDERS Revised February 17, 2026 In the course of your service for or employment with Pediatrix Medical Group, Inc. (“Pediatrix”) and the subsidiaries through which its businesses are conducted, including PMG Servic
February 19, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
February 19, 2026	10-K	Pediatrix Medical Group, Inc. INDEX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number 001-12111 Pediatrix Medical Group, Inc. (Exact nam
February 19, 2026	EX-21.1	Number of Omitted Subsidiaries Operating Exhibit 21.1 Subsidiaries The list below excludes subsidiaries in the same line of business and includes the immediate parent of each excluded subsidiary. The list also excludes subsidiaries that in the aggregate, as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2025. Number of Omitted Subsidiaries Operating Immediate Parent State of Incorporation Line of Bu
February 19, 2026	EX-99.1	Pediatrix Medical Group Reports Fourth Quarter Results FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 [email protected] FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Fourth Quarter Results FORT LAUDERDALE, Fla., February 19, 2026 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.40 per share for the t
November 3, 2025	10-Q	Consolidated Statements of Income and Comprehensive Income for the Three and Nine Months Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures PART II - OTHER INFORMATION Legal Proceedings Risk Factors SIGNATURES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medica
November 3, 2025	EX-99.1	Pediatrix Medical Group Reports Third Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 [email protected] FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Third Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FORT LAUDERDALE, Fla., November 3, 2025 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, to
November 3, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
August 18, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commi
August 18, 2025	EX-99.1	Executive Vice President, Chief Financial Officer & Treasurer FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 [email protected] FOR IMMEDIATE RELEASE Pediatrix Medical Group Announces $250 Million Share Repurchase Program FORT LAUDERDALE, Fla., August 18, 2025 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced that its Board of Dir
August 5, 2025	EX-10.1	Employment Agreement, dated as of August 1, 2025, by and between PMG Services, Inc. and Don Gregory Neeb. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC., a Florida corporation (“Employer”), and DON GREGORY NEEB (“Employee”) on August 1, 2025 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’s Business” as defined on Exhibit A hereto; and WHEREAS, Employer desires to employ Empl
August 5, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commi
August 5, 2025	EX-99.1	Pediatrix Medical Group Reports Second Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 [email protected] FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FORT LAUDERDALE, Fla., August 5, 2025 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, tod
August 5, 2025	10-Q	Consolidated Statements of Income and Comprehensive Income for the Three and Six Months Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures PART II - OTHER INFORMATION Legal Proceedings Risk Factors SIGNATURES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gro
July 1, 2025	EX-99.1	Pediatrix Board Appoints Kurt D. Newman, M.D. as Independent Director FOR MORE INFORMATION: Kasandra Rossi Executive Vice President, Chief Financial Officer and Treasurer 954-692-7163 kasandra.
July 1, 2025	8-K	FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commiss
May 8, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 6, 2025	10-Q	Consolidated Statements of Income and Comprehensive Income for the Three Months Ended March 31, 2025 and 2024 (Unaudited) Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures PART II - OTHER INFORMATION Legal Proceedings UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gr
May 6, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 6, 2025	EX-99.1	Pediatrix Medical Group Reports First Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 [email protected] FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports First Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FORT LAUDERDALE, Fla., May 6, 2025 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today r
April 18, 2025	8-K	FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commis
March 28, 2025	DEFA14A	20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
March 28, 2025	DEF 14A	20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
March 28, 2025	ARS	ARS 2024 ANNUAL REPORT Take great care of the patient, every day and in every way.™ Corporate Profile: Pediatrix ® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and offi
February 20, 2025	EX-99.1	Pediatrix Medical Group Reports Fourth Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
February 20, 2025	EX-19	Pediatrix Medical Group, Inc. Policy Statement on Inside Information and Insider Trading For Directors, Management Insiders, Financial Insiders, Systems Insiders and Other Insiders. Exhibit 19 PEDIATRIX MEDICAL GROUP, INC. POLICY STATEMENT ON INSIDE INFORMATION AND INSIDER TRADING FOR DIRECTORS, MANAGEMENT INSIDERS, FINANCIAL INSIDERS, SYSTEMS INSIDERS AND OTHER INSIDERS Revised February 18, 2025 In the course of your service for or employment with Pediatrix Medical Group, Inc. (“Pediatrix”) and the subsidiaries through which its businesses are conducted, including PMG Servic
February 20, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
February 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number 001-12111 Pediatrix Medical Group, Inc. (Exact nam
February 20, 2025	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries Number of Omitted Subsidiaries Operating State of Incorporation Line of Business in the United States in Foreign Countries Pediatrix Medical Group, Inc. Florida Physician Services 7 0 Pediatrix Management Services, Inc. Florida Physician Services 10 0
February 20, 2025	EX-10.19	Employment Agreement, dated as of January 12, 2025, by and between PMG Services, Inc., Pediatrix Medical Group, Inc. and Mark Ordan.* Exhibit 10.19 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC., a Florida corporation (“Employer”), PEDIATRIX MEDICAL GROUP, INC., a Florida corporation and parent of Employer (“Pediatrix”), and MARK ORDAN (“Employee”) on January 12, 2025 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’
January 14, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Comm
January 13, 2025	EX-99.1	Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and H
January 13, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Comm
December 5, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
November 13, 2024	SC 13G	MD / Pediatrix Medical Group, Inc. / Rubric Capital Management LP - SC 13G Passive Investment SC 13G 1 tm2427812d15sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pediatrix Medical Group, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 58502B106 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate b
November 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medica
November 1, 2024	EX-99.1	Pediatrix Medical Group Reports Third Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
November 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
November 1, 2024	EX-10.1	Third Amended and Restated Employment Agreement, dated as of September 30, 2024, by and between PMG Services, Inc. and Kasandra Rossi. Exhibit 10.1 THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC. (f/k/a Mednax Services, Inc.), a Florida corporation (“Employer”), and KASANDRA ROSSI (“Employee”) on September 30, 2024. RECITALS WHEREAS, Employer is presently engaged in “Employer’s Business” as defined on
October 31, 2024	SC 13G/A	MD / Pediatrix Medical Group, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Pediatrix Medical Group Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commi
August 6, 2024	EX-10.1	Master Services Agreement, dated as of April 19, 2024, by and between Guidehouse Managed Services LLC and PMG Services, Inc. Exhibit 10.1 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”) is entered into on April 19, 2024 (the “Effective Date”) by and between Guidehouse Mana
August 6, 2024	EX-99.1	Pediatrix Medical Group Reports Second Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gro
June 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commiss
June 10, 2024	SC 13G/A	MD / Pediatrix Medical Group, Inc. / EARNEST PARTNERS LLC - PEDIATRIX MEDICAL GROUP, INC. - 05/31/2024 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3) Pediatrix Medical Group, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) 05/31/2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
May 30, 2024	EX-99.1	Pediatrix Medical Group, Inc. (NYSE:MD) Supplemental Disclosure May 30, 2024 Pediatrix Medical Group, Inc. (NYSE:MD) Supplemental Disclosure May 30, 2024 2024 Operational Updates Continued focus on operating efficiency and stabilization of margin profile. Previously announced portfolio optimization on track to be completed before end of 2024. Company is exiting a meaningful number of office-based practices and its primary and urgent care business. Annualized Adj. EBITDA im
May 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 7, 2024	EX-99.1	Pediatrix Medical Group Reports First Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
May 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gr
April 25, 2024	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commis
March 28, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 28, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 28, 2024	ARS	ARS Take great care of the patient, every day in every way. TM 2023 ANNUAL REPORTCorporate Profile: Pediatrix ® Medical Group, Inc. (NYSE:MD) is the nation’s leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings
February 20, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries Number of Omitted Subsidiaries Operating State of Incorporation Line of Business in the United States in Foreign Countries Pediatrix Medical Group, Inc. Florida Physician Services 7 0 Pediatrix Management Services, Inc. Florida Physician Services 9 0
February 20, 2024	EX-10.15	Second Amended and Restated Employment Agreement, dated as of April 26, 2023, by and between PMG Services, Inc. and Curtis B. Pickert, M.D.* Exhibit 10.15 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC. (f/k/a Mednax Services, Inc.), a Florida corporation (“Employer”), and CURTIS B. PICKERT, M.D. (“Employee”) on April 26, 2023 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Emp
February 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
February 20, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number 001-12111 Pediatrix Medical Group, Inc. (Exact nam
February 20, 2024	EX-99.1	Three Months Ended December 31, 2023 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
February 20, 2024	EX-10.17	Second Amended and Restated Employment Agreement, dated as of April 26, 2023, by and between PMG Services, Inc. and Lee Wood.* Exhibit 10.17 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC. (f/k/a Mednax Services, Inc.), a Florida corporation (“Employer”), and LEE WOOD (“Employee”) on April 26, 2023 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’s Busines
February 20, 2024	EX-97.1	Pediatrix Medical Group, Inc. Policy on Recoupment of Incentive Compensation Exhibit 97.1 PEDIATRIX MEDICAL GROUP, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of Pediatrix Medical Group, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by t
February 14, 2024	SC 13G/A	MD / Pediatrix Medical Group, Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Pediatrix Medical Group Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat
February 13, 2024	SC 13G/A	MD / Pediatrix Medical Group, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Pediatrix Medical Group Inc Title of Class of Securities: Common Stock CUSIP Number: 58502B106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 12, 2024	SC 13G/A	MD / Pediatrix Medical Group, Inc. / EARNEST PARTNERS LLC - PEDIATRIX MEDICAL GROUP, INC. - 12/31/2023 Passive Investment SC 13G/A 1 md13g2nd1223.txt PEDIATRIX MEDICAL GROUP, INC. - 12/31/2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) Pediatrix Medical Group, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) 12/31/2023 - (Date of Event Which Requires Filing of this State
February 9, 2024	SC 13G	MD / Pediatrix Medical Group, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pediatrix Medical Group Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
January 22, 2024	SC 13G/A	MD / Pediatrix Medical Group, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us58502b1061012224.txt us58502b1061012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 13) Pediatrix Medical Group, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the app
November 2, 2023	EX-99.1	Pediatrix Medical Group Reports Third Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
November 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
November 2, 2023	10-Q	t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medi
August 16, 2023	LETTER	LETTER United States securities and exchange commission logo August 16, 2023 James D. Swift, M.D. Chief Executive Officer Pediatrix Medical Group, Inc. 1301 Concord Terrace Sunrise, FL 33323 Re: Pediatrix Medical Group, Inc. Definitive Proxy Statement on Schedule 14A Filed March 31, 2023 File No. 001-12111 Dear James D. Swift: We have completed our review of your filing. We remind you that the company an
August 8, 2023	CORRESP	August 8, 2023 August 8, 2023 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance Disclosure Review Program 100 F Street, N.E. Washington, DC 20549 Attention: Eric Envall and Charlie Guidry Re: Pediatrix Medical Group, Inc. Definitive Proxy Statement on Schedule 14A Filed March 31, 2023 File No. 001-12111 Ladies and Gentlemen: This letter is in response to the comment fro
August 3, 2023	10-Q	t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical G
August 3, 2023	EX-3.1	Second Amended and Restated By-laws of Pediatrix Medical Group, Inc. (incorporated by reference to Exhibit 3.1 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended June 30, 2023). Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF PEDIATRIX MEDICAL GROUP, INC. (A FLORIDA CORPORATION) Effective July 31, 2023 INDEX ARTICLE ONE OFFICES 3 Section 1. Registered Office 3 Section 2. Principal Office 3 Section 3. Other Offices 3 ARTICLE TWO MEETINGS OF SHAREHOLDERS 3 Section 1. Place 3 Section 2. Time of Annual Meeting 3 Section 3. Call of Special Meetings 3 Section 4. Conduct of Me
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commi
August 3, 2023	EX-99.1	Pediatrix Medical Group Reports Second Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
July 27, 2023	LETTER	LETTER United States securities and exchange commission logo July 27, 2023 James D. Swift, M.D. Chief Executive Officer Pediatrix Medical Group, Inc. 1301 Concord Terrace Sunrise, FL 33323 Re: Pediatrix Medical Group, Inc. Definitive Proxy Statement on Schedule 14A Filed March 31, 2023 File No. 001-12111 Dear James D. Swift: We have limited our review of your most recent definitive proxy statement to tho
May 11, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 10, 2023	SC 13G/A	MD / Pediatrix Medical Group Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Pediatrix Medical Group Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) April 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
May 4, 2023	EX-99	Pediatrix Board Appoints Sylvia Young as Independent Director FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 2, 2023	EX-4	Eighth Supplemental Indenture dated as of March 31, 2023 to the Indenture, dated as of December 8, 2015, by and among Pediatrix Medical Group, Inc. (f/k/a Mednax, Inc.), certain of its subsidiaries and U.S. Bank Trust Company, National Association, as Trustee. (incorporated by reference to Exhibit 4.1 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended March 31, 2023). Execution Version PEDIATRIX MEDICAL GROUP, INC. TO U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY the guarantors named herein EIGHTH SUPPLEMENTAL INDENTURE Dated as of March 31, 2023 to the INDENTURE Dated as of December 8, 2015 GUARANTEES OF 5.375% SENIOR NOTES DUE 2030 EIGHTH SUPPLEMENTAL INDENTURE 5.375% Senior Notes due 2030 THIS EIGHTH S
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commissi
May 2, 2023	EX-10	Amended and Restated Employment Agreement, dated as of April 26, 2023, by and between PMG Services, Inc. and C. Marc Richards (incorporated by reference to Exhibit 10.2 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended March 31, 2023).* AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC.
May 2, 2023	EX-10	Third Amended and Restated Employment Agreement, dated as of April 26, 2023, by and between PMG Services, Inc. and James D. Swift, M.D. (incorporated by reference to Exhibit 10.1 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended March 31, 2023).* THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC.
May 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gr
May 2, 2023	EX-99	Pediatrix Medical Group Reports First Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
May 2, 2023	EX-10	Second Amended and Restated Employment Agreement, dated as of April 26, 2023, by and between PMG Services, Inc. and Mary Ann E. Moore (incorporated by reference to Exhibit 10.3 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended March 31, 2023).* SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between PMG SERVICES, INC.
March 31, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
March 31, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a P arty o ther t han the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(
March 31, 2023	ARS	ARS Take great care of the paent, every day in every way.™ 2022 ANNUAL REPORTCorporate Profile: Pediatrix ® Medical Group, Inc. (NYSE:MD) is the nation’s leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and
March 31, 2023	DEF 14A	DEF 14A Take great care of the paent, every day in every way.™ 2023 Notice of Annual Meeting of Shareholders and Proxy Statement1301 Concord Terrace Sunrise, Florida 33323-2825 (954) 384-0175 Dear Pediatrix Shareholder: You are cordially invited to attend the 2023 Annual Shareholders’ Meeting of Pediatrix Medical Group, Inc. (“Pediatrix”, the “Company”, “we” or “our”) on Thursday, May 11, 2023, beginning
March 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commis
February 17, 2023	EX-99	Pediatrix Medical Group Reports Fourth Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
February 17, 2023	EX-21	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries Number of Omitted Subsidiaries Operating State of Incorporation Line of Business in the United States in Foreign Countries Pediatrix Medical Group, Inc. Florida Physician Services 9 0 Pediatrix Management Services, Inc. Florida Physician Services 9 0
February 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
February 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number 001-12111 Pediatrix Medical Group, Inc. (Exact nam
February 14, 2023	SC 13G/A	MD / MEDNAX Inc / EARNEST PARTNERS LLC - PEDIATRIX MEDICAL GROUP, INC.- 12/31/2022 Passive Investment SC 13G/A 1 md13g2nd1222.txt PEDIATRIX MEDICAL GROUP, INC.- 12/31/2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) Pediatrix Medical Group, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) 12/31/2022 - (Date of Event Which Requires Filing of this Statem
February 14, 2023	SC 13G/A	MD / MEDNAX Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Pediatrix Medical Group Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 9, 2023	SC 13G/A	MD / MEDNAX Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01645-pediatrixmedicalgrou.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Pediatrix Medical Group Inc. Title of Class of Securities: Common Stock CUSIP Number: 58502B106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate
February 9, 2023	SC 13G/A	MD / MEDNAX Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 PEDIATRIX MEDICAL GROUP INC COMMON STOCK Cusip #58502B106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #58502B106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,439 Item 6: 0 Item 7: 12,310 Item 8: 0 Item 9
January 23, 2023	SC 13G/A	MD / MEDNAX Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us58502b1061012323.txt us58502b1061012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) Pediatrix Medical Group, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the app
January 20, 2023	SC 13D/A	MD / MEDNAX Inc / Starboard Value LP - AMENDMENT NO. 6 TO THE SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da60629728001202023.htm AMENDMENT NO. 6 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Pediatrix Medical Group, Inc. (Name of Issuer) Common Stock, par value $0.01
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
December 16, 2022	EX-99.1	Pediatrix Announces Leadership Transitions James D. Swift, M.D., Appointed Chief Executive Officer; Mark S. Ordan Appointed Executive Chair of Board of Directors FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
December 2, 2022	SC 13D/A	MD / MEDNAX Inc / Starboard Value LP - AMENDMENT NO. 5 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 5)1 Pediatrix Medical Group, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 58502B106 (CUSIP Number) JEFFREY
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Com
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medica
November 3, 2022	EX-99.1	Pediatrix Medical Group Reports Third Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
September 23, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 19, 2022 Pediatrix Medical Group, Inc. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Co
August 4, 2022	EX-99.1	Pediatrix Medical Group Reports Second Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Pediatrix Medical Group, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commi
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Pediatrix Medical Gro
August 4, 2022	EX-3.1	Second Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended June 30, 2022). SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF PEDIATRIX MEDICAL GROUP, INC.
August 4, 2022	EX-10.1	Second Amended and Restated Employment Agreement, effective August 1, 2022, by and between PMG Services, Inc. and James D. Swift, M.D SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into by and between PMG SERVICES, INC.
June 21, 2022	EX-99.1	Mednax To Change Name to Pediatrix Medical Group, Inc. Effective July 1, 2022 EX-99.1 2 md-ex991.htm EX-99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE Mednax To Change Name to Pediatrix Medical Group, Inc. Effective July 1, 2022 FORT LAUDERDALE, Fla., June 21, 2022 - Mednax, Inc. (NYSE: MD) today announced that it will change its corporate name to Pediatrix Medical Group
June 21, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 17, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
April 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Mednax, Inc. (Exact
April 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
April 28, 2022	EX-99.1	Mednax Reports First Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charleslynch@mednax.
April 1, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted
April 1, 2022	DEF 14A	DEF 14A
April 1, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
March 21, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted
February 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 17, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 17, 2022	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries Number of Omitted Subsidiaries Operating ? State of Incorporation Line of Business in the United States in Foreign Countries Mednax Services, Inc. Florida Physician Services 10 0 Pediatrix Medical Group, Inc. Florida Physician Services 10 0
February 17, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number 001-12111 Mednax, Inc. (Exact name of registrant a
February 17, 2022	EX-10.18	Amended and Restated Employment Agreement, effective February 15, 2022, by and between Mednax Services, Inc. and Mary Ann E. Moore.* Exhibit 10.18 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (?Employer?), and MARY ANN E. MOORE (?Employee?) effective as of February 15, 2022 (the ?Effective Date?). RECITALS WHEREAS, Employer is presently engaged in ?Employer?s Business? as defined on
February 17, 2022	EX-99.1	Mednax Reports Fourth Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charleslynch@mednax.
February 14, 2022	EX-99.1	Mednax Announces Closing of $1.1 Billion in Financing Transactions Redeems 6.25% Senior Notes Due 2027 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 [email protected] FOR IMMEDIATE RELEASE Mednax Announces Closing of $1.1 Billion in Financing Transactions Redeems 6.25% Senior Notes Due 2027 FORT LAUDERDALE, Fla. ? February 14, 2022 - Mednax, Inc. (NYSE: MD) (?Mednax?) announced today that on February 11, 2022 it closed the
February 14, 2022	EX-10.1	Amendment No.4, dated as of February 11, 2022, to the Credit Agreement, dated as of October 30, 2017, among Mednax, Inc., certain of its domestic subsidiaries from time to time party thereto as guarantors, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to Pediatrix’s Current Report on Form 8-K filed on February 14, 2022). Exhibit 10.1 AMENDMENT NO. 4 TO CREDIT AGREEMENT AMENDMENT NO. 4 dated as of February 11, 2022 (this ?Amendment?), to the Credit Agreement, dated as of October 30, 2017 (as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with its terms prior to the date hereof, the ?Existing Credit Agreement?), among MEDNAX, INC., a Florida corporation (the ?Borrowe
February 14, 2022	SC 13G/A	MD / MEDNAX Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 14, 2022	EX-4.3	Seventh Supplemental Indenture dated as of February 11, 2021 to the Indenture, dated as of December 8, 2015, by and among Mednax, Inc., certain of its subsidiaries and U.S. Bank National Association, as Trustee (incorporated by reference to Exhibit 4.3 to Pediatrix’s Current Report on Form 8-K filed on February 14, 2022). Exhibit 4.3 MEDNAX, INC. TO U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, As Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN SEVENTH SUPPLEMENTAL INDENTURE Dated as of February 11, 2022 to the INDENTURE Dated as of December 8, 2015 5.375% SENIOR NOTES DUE 2030 TABLE OF CONTENTS Page Article I RELATION TO BASE INDENTURE; DEFINITIONS Section 1.01. Relation to Base I
February 14, 2022	SC 13G/A	MD / MEDNAX Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MEDNAX Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 11, 2022	SC 13G/A	MD / MEDNAX Inc / EARNEST PARTNERS LLC - MEDNAX, INC. - 12/31/2021 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1) MEDNAX, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) 12/31/2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 10, 2022	SC 13G/A	MD / MEDNAX Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: MEDNAX Inc. Title of Class of Securities: Common Stock CUSIP Number: 58502B106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 1
February 9, 2022	SC 13G	MD / MEDNAX Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 MEDNAX INC COMMON STOCK Cusip #58502B106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #58502B106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,305,461 Item 6: 0 Item 7: 5,555,578 Item 8: 0 Item 9: 5,555,578 Item 11: 6.426% Ite
January 27, 2022	SC 13G/A	MD / MEDNAX Inc / BlackRock Inc. Passive Investment us58502b1061012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) MEDNAX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 26, 2022	SC 13G/A	MD / MEDNAX Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us58502b1061012522.txt us58502b1061012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) MEDNAX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
November 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
November 19, 2021	EX-3.1	Amended and Restated By-laws of Mednax, Inc. (incorporated by reference to Exhibit 3.1 to Mednax’s Current Report on Form 8-K dated November 19, 2021). AMENDED AND RESTATED BYLAWS OF MEDNAX, INC. (A FLORIDA CORPORATION) Effective November 16, 2021 INDEX Article One OFFICES 3 Section 1. Registered Office 3 Section 2. Principal Office 3 Section 3. Other Offices 3 Article Two MEETINGS OF SHAREHOLDERS 3 Section 1. Place 3 Section 2. Time of Annual Meeting 3 Section 3. Call of Special Meetings 3 Section 4. Conduct of Meetings 3 Section 5. Notice and W
October 28, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Mednax, Inc. (Ex
October 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
October 28, 2021	EX-99.1	Mednax Reports Third Quarter Results FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charleslynch@mednax.
August 31, 2021	SC 13D/A	MD / MEDNAX Inc / Starboard Value LP - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 4)1 MEDNAX, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 58502B106 (CUSIP Number) JEFFREY C. SMITH STARBOAR
August 27, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 Mednax, Inc. (Exact name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Mednax, Inc. (Exact n
August 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2021 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
August 6, 2021	EX-99.1	Mednax Reports Second Quarter Results Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE Mednax Reports Second Quarter Results FORT LAUDERDALE, Fla., August 6, 2021 - Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal, and pediatric services, today reported earnings from continuing operations
August 6, 2021	S-8	As filed with the Securities and Exchange Commission on August 6, 2021 As filed with the Securities and Exchange Commission on August 6, 2021 Registration No.
August 6, 2021	EX-10.3	Services Agreement, dated May 12, 2021, by and between Mednax Services, Inc. and R1 RCM Inc. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
August 6, 2021	S-8	As filed with the Securities and Exchange Commission on August 6, 2021 As filed with the Securities and Exchange Commission on August 6, 2021 Registration No.
May 17, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2021 Mednax, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2021 Mednax, Inc. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
May 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2021 Mednax, Inc. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
May 7, 2021	EX-99.1	Mednax Reports First Quarter Results EX-99.1 2 d420793dex991.htm EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE Mednax Reports First Quarter Results FORT LAUDERDALE, Fla., May 7, 2021—Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal, and pediatric services, today reported earni
May 7, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Me
May 7, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2021 Mednax, Inc. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
March 23, 2021	DEF 14A	COURTESY PDF
March 23, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
March 23, 2021	DEF 14A	Amended and Restated Mednax, Inc. 1996 Non-Qualified Employee Stock Purchase Plan (incorporated by reference to Exhibit B to the Company’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 23, 2021). Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted
February 18, 2021	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries Number of Omitted Subsidiaries Operating Name of Subsidiary State of Incorporation Line of Business in the United States in Foreign Countries Mednax Services, Inc. Florida Physician Services 9 0 Pediatrix Medical Group, Inc. Florida Physician Services 10 0
February 18, 2021	EX-99.1	Mednax Reports Fourth Quarter Results EX-99.1 2 d145273dex991.htm EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE Mednax Reports Fourth Quarter Results FORT LAUDERDALE, Fla., February 18, 2021 - Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal, and pediatric services, today repor
February 18, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 18, 2021 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 18, 2021	EX-10.21	Amended and Restated Employment Agreement, dated as of September 27, 2020, by and between Mednax Services, Inc. and Roger Mack Hinson, M.D. (incorporated by reference to Exhibit 10.24 to Pediatrix’s Annual Report on Form 10-K for the year ended December 31, 2020).* Exhibit 10.21 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (?Employer?), and Roger Mack Hinson, M.D. (?Employee?) effective as of September 27, 2020 (the ?Effective Date?). RECITALS WHEREAS, Employer is presently engaged in ?Employer?s Business? as def
February 18, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12111 MEDNAX, INC
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEDNAX, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 16, 2021	SC 13G	MEDNAX, INC. - 12/31/2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) MEDNAX, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) 12/31/2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 12, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MEDNAX Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: MEDNAX Inc. Title of Class of Securities: Common Stock CUSIP Number: 58502B106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
February 8, 2021	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MEDNAX Inc (Name of Issuer) Common Stock (Title of Class of Securities) 58502B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f
January 26, 2021	SC 13G/A	SC 13G/A us58502b1061012621.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) MEDNAX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
December 21, 2020	EX-99.2	MEDNAX Completes Sale of MEDNAX Radiology Solutions to Radiology Partners EX-99.2 Exhibit 99.2 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 [email protected] NOT FOR IMMEDIATE RELEASE MEDNAX Completes Sale of MEDNAX Radiology Solutions to Radiology Partners FORT LAUDERDALE, Fla. – December 16, 2020 - MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in prenatal, neonatal, and pedia
December 21, 2020	EX-99.1	UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION Overview On December 15, 2020, Mednax, Inc., a Florida corporation (“the “Company”), pursuant to the previously disclosed Securities Purchase Agreement, dated as of September 9, 2020, by and between Mednax Services, Inc., a Florida corporation (“Mednax Services”), and Radiology Partners, Inc., a Delaware corporation (“Buye
December 21, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Completion of Acquisition or Disposition of Assets, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 15, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
December 10, 2020	SC 13G/A	MD / Mednax, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: MEDNAX Inc. Title of Class of Securities: Common Stock CUSIP Number: 58502B106 Date of Event Which Requires Filing of this Statement: November 30, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
November 24, 2020	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 23, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
November 6, 2020	EX-99.1	MEDNAX Reports Third Quarter Results EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Reports Third Quarter Results FORT LAUDERDALE, Fla., November 6, 2020—MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in prenatal, neonatal, and pediatric services, today reported a net loss of $41
November 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-1211
November 6, 2020	EX-10.4	Employment Agreement, effective September 8, 2020, by and between Mednax Services, Inc. and C. Marc Richards (incorporated by reference to Exhibit 10.4 to Mednax’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on November 6, 2020).* EX-10.4 Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and C. Marc Richards (“Employee”) on September 27, 2020 and effective as of September 8, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’s Business” as defined on Exhibit A
November 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
November 6, 2020	EX-10.5	Employment Agreement, effective September 27, 2020, by and between Mednax Services, Inc. and Dominic J. Andreano (incorporated by reference to Exhibit 10.5 to Mednax’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on November 6, 2020).* EX-10.5 Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and Dominic J. Andreano (“Employee”) effective as of September 27, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’s Business” as
September 29, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 27, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Num
September 15, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 9, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
September 15, 2020	EX-2.1	Securities Purchase Agreement, dated as of September 9, 2020, by and between Mednax Services, Inc. and Radiology Partners, Inc. (incorporated by reference to Exhibit 2.1 to Pediatrix’s Current Report on Form 8-K filed on September 15, 2020). EX-2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit 2.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT BY AND BETWEEN MEDNAX SERVICES, INC., AND RADIOLOGY PARTNERS, INC. DATED AS OF SEPTEMBER 9, 2020 TABLE OF
September 10, 2020	EX-99.1	MEDNAX Announces Agreement to Sell MEDNAX Radiology Solutions to Radiology Partners Transaction Enables Singular Focus on Pediatrix and Obstetrix Medical Groups EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Announces Agreement to Sell MEDNAX Radiology Solutions to Radiology Partners Transaction Enables Singular Focus on Pediatrix and Obstetrix Medical Groups FORT LAUDERDALE, Fla. – September 10, 2020 — MEDNAX, Inc. (NYSE: MD),
September 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 9, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 25, 2020	EX-99.1	MEDNAX Announces Financial Leadership Transition C. Marc Richards Appointed Executive Vice President, to Succeed Stephen D. Farber as Chief Financial Officer EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Announces Financial Leadership Transition C. Marc Richards Appointed Executive Vice President, to Succeed Stephen D. Farber as Chief Financial Officer FORT LAUDERDALE, Fla. — August 25, 2020 — MEDNAX, Inc. (NYSE: MD), the n
August 25, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number
July 30, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 MED
July 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
July 30, 2020	EX-10.1	Employment Agreement, dated July 12, 2020, by and between Mednax Services, Inc. and Mark S. Ordan (incorporated by Reference to Exhibit 10.1 to Mednax’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed on July 30, 2020).* EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), MARK ORDAN (“Employee”), and solely for purposes of Sections 1.1, 2.2, 3.4, 5.13 and 8.7 hereof, MEDNAX, INC., a Florida corporation and the parent corporation of Employer (“MEDNAX”), effective as of July 12, 2020
July 30, 2020	EX-99.1	MEDNAX Reports Second Quarter Results Results from Continuing Operations Reflect Significant Recovery in Second Half of Quarter Following Initial Disruption from COVID-19 Company Anticipates Full Normalization of Patient Volumes across All Service Li EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Reports Second Quarter Results Results from Continuing Operations Reflect Significant Recovery in Second Half of Quarter Following Initial Disruption from COVID-19 Company Anticipates Full Normalization of Patient Volumes acr
July 28, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
July 28, 2020	DEF 14A	- DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.
July 28, 2020	DEF 14A	- COURTESY PDF begin 644 d941102ddef14a1.pdf M)5!$1BTQ+C8-)>+CS],-"C$@,"!O8FH/#PO365T861A=&$@,B P(%(O4&%G M97,@,R P(%(O5'EP92]#871A;&]G/CX96YD;V)J"C(@,"!O8FH*/#PO3&5N M9W1H(#,R-C8O4W5B='EP92]834PO5'EP92]-971A9&%T83X^G)E4WI.5&-Z M:V,Y9"(/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X M.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C8M8S Q-2 X,2XQ-3DX,#DL(#(P M,38O,3$O,3$M,#$Z-#(Z,38@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
July 13, 2020	EX-99.1	[The remainder of this page intentionally left blank] Exhibit 99.1 Execution Version AGREEMENT This Agreement (this “Agreement”) is made and entered into as of July 12, 2020 by and among MEDNAX, Inc. (the “Company”) and the entities and natural persons set forth in the signature pages hereto (collectively, “Starboard”) (each of the Company and Starboard, a “Party” to this Agreement, and collectively, the “Parties”). RECITALS WHEREAS, the Company and
July 13, 2020	EX-10.4	SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.4 Exhibit 10.4 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”) is entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and Dominic J. Andreano (“Employee”) on July 12, 2020, and shall be effective as such date (“Effective Date”). RECITALS WHER
July 13, 2020	EX-10.2	SEPARATION AGREEMENT EX-10.2 Exhibit 10.2 Execution Version SEPARATION AGREEMENT This Separation Agreement (this “Agreement ”) is hereby made and entered into between MEDNAX SERVICES, INC., f/k/a PEDIATRIX MEDICAL GROUP, INC., a Florida corporation (“Employer ”), and ROGER J. MEDEL, M.D. (“Employee ”) to be effective as set forth in Section 10 below. Employer and Employee may be referred to herein as a “Party ” and, t
July 13, 2020	EX-10.1	[The remainder of this page intentionally left blank] EX-10.1 Exhibit 10.1 Execution Version AGREEMENT This Agreement (this “Agreement”) is made and entered into as of July 12, 2020 by and among MEDNAX, Inc. (the “Company”) and the entities and natural persons set forth in the signature pages hereto (collectively, “Starboard”) (each of the Company and Starboard, a “Party” to this Agreement, and collectively, the “Parties”). RECITALS WHEREAS, the Comp
July 13, 2020	EX-10.3	SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.3 Exhibit 10.3 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”) is entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and Stephen D. Farber (“Employee”) on July 12, 2020, and shall be effective as such date (“Effective Date”). RECITALS WHEREA
July 13, 2020	EX-99.2	JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.01 per share, of MEDNAX, Inc. This Joint Filing Agreement shal
July 13, 2020	EX-10.2	Separation Agreement, dated July 12, 2020, by and between Mednax Services, Inc. and Roger J. Medel, M.D. (incorporated by reference to Exhibit 10.2 to Mednax’s Current Report on Form 8-K filed on July 13, 2020).* EX-10.2 Exhibit 10.2 Execution Version SEPARATION AGREEMENT This Separation Agreement (this “Agreement ”) is hereby made and entered into between MEDNAX SERVICES, INC., f/k/a PEDIATRIX MEDICAL GROUP, INC., a Florida corporation (“Employer ”), and ROGER J. MEDEL, M.D. (“Employee ”) to be effective as set forth in Section 10 below. Employer and Employee may be referred to herein as a “Party ” and, t
July 13, 2020	EX-99.1	MEDNAX Announces Leadership and Board Transitions Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J. Medel, M.D. Guy P. Sansone Appointed Chair of Board of Directors Significant Board Refreshment, With Five New Indep EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Announces Leadership and Board Transitions Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J. Medel, M.D. Guy P. Sansone Appointed Chair of Board of Directors Significant Board Refreshment,
July 13, 2020	EX-10.1	Agreement, dated as of July 12, 2020, by and among Mednax, Inc., Starboard Value LP and certain of its affiliates (incorporated by reference to Exhibit 10.1 to Mednax’s Current Report on Form 8-K filed on July 13, 2020). EX-10.1 Exhibit 10.1 Execution Version AGREEMENT This Agreement (this “Agreement”) is made and entered into as of July 12, 2020 by and among MEDNAX, Inc. (the “Company”) and the entities and natural persons set forth in the signature pages hereto (collectively, “Starboard”) (each of the Company and Starboard, a “Party” to this Agreement, and collectively, the “Parties”). RECITALS WHEREAS, the Comp
July 13, 2020	SC 13D/A	MD / Mednax, Inc. / Starboard Value LP - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 MEDNAX, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 58502B106 (CUSIP Number) JEFFREY C. SMITH STARBOAR
July 13, 2020	EX-99.1	MEDNAX Announces Leadership and Board Transitions Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J. Medel, M.D. Guy P. Sansone Appointed Chair of Board of Directors Significant Board Refreshment, With Five New Indep EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Announces Leadership and Board Transitions Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J. Medel, M.D. Guy P. Sansone Appointed Chair of Board of Directors Significant Board Refreshment,
July 13, 2020	EX-10.3	Second Amendment to Amended and Restated Employment Agreement, dated as of July 12, 2020, by and between MEDNAX Services, Inc. and Stephen D. Farber. EX-10.3 Exhibit 10.3 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”) is entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and Stephen D. Farber (“Employee”) on July 12, 2020, and shall be effective as such date (“Effective Date”). RECITALS WHEREA
July 13, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 12, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File
July 13, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 12, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
July 13, 2020	EX-10.4	Second Amendment to Amended and Restated Employment Agreement, dated as of July 12, 2020, by and between MEDNAX Services, Inc. and Dominic J. Andreano. EX-10.4 Exhibit 10.4 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”) is entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and Dominic J. Andreano (“Employee”) on July 12, 2020, and shall be effective as such date (“Effective Date”). RECITALS WHER
July 10, 2020	SC 13G/A	MD / Mednax, Inc. / BlackRock Inc. Passive Investment us58502b1061071020.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) MEDNAX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58502B106 - (CUSIP Number) June 30, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
June 15, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 12, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
June 15, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 12, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File
June 5, 2020	EX-99.1	MEDNAX Announces Significant Progress in Strategic Transformation Company Intends to Return to Original Name, Pediatrix Medical Group; to Refocus as Dedicated Pediatrics & Obstetrics Organization Announces Intent to Sell MEDNAX Radiology Solutions Re EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Announces Significant Progress in Strategic Transformation Company Intends to Return to Original Name, Pediatrix Medical Group; to Refocus as Dedicated Pediatrics & Obstetrics Organization Announces Intent to Sell MEDNA
June 5, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
June 5, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File N
May 15, 2020	EX-99.1	AMENDED AND RESTATED JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 AMENDED AND RESTATED JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are shareholders, direct or beneficial, of MEDNAX, Inc., a Florida corporation (the “Company”); WHEREAS, Starboard Value and Opportunity Master Fund Ltd, a Cayman Islands exempted company (“Starboard V&O Fund”), Starboard Value and Opportunity S LLC, a Delaware limited liability company (“
May 15, 2020	SC 13D/A	MD / Mednax, Inc. / Starboard Value LP - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.
May 12, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
May 12, 2020	EX-99.1	UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Overview On May 6, 2020, MEDNAX, Inc., a Florida corporation (the “Company”), through MEDNAX Services, Inc., a Florida corporation and wholly-owned subsidiary of the Company, entered into a Securities Purchase Agreement with NMSC II, LLC, a Delaware limited liability company (“Buyer”) and an affiliate of North Am
May 12, 2020	EX-2.1	Securities Purchase Agreement, dated as of May 6, 2020, by and between Mednax Services, Inc. and NMSC II, LLC (incorporated by reference to Exhibit 2.1 to Pediatrix’s Current Report on Form 8-K filed on May 12, 2020). EX-2.1 Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EXECUTION VERSION SECURITIES PURCHASE AGREEMENT BY AND BETWEEN MEDNAX SERVICES, INC., AND NMSC II, LLC DATED AS OF MAY 6, 2020 TABLE OF CONTENTS ARTICLE 1
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
May 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 ME
May 7, 2020	EX-99.1	MEDNAX Reports First Quarter Results Completes Sale of American Anesthesiology to North American Partners in Anesthesia EX-99.1 Exhibit 99.1 FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 [email protected] FOR IMMEDIATE RELEASE MEDNAX Reports First Quarter Results Completes Sale of American Anesthesiology to North American Partners in Anesthesia FORT LAUDERDALE, Fla., May 7, 2020 - MEDNAX, Inc. (NYSE: MD), the national health solutions partner speciali
May 7, 2020	EX-10.1	Amendment No.3, dated as of March 25, 2020, to the Credit Agreement, dated as of October 30, 2017, among Mednax, Inc., certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. (incorporated by reference to Exhibit 10.1 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended March 31, 2020). EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 3 TO CREDIT AGREEMENT AMENDMENT NO. 3 dated as of March 25, 2020 (this “Amendment”), to the Credit Agreement, dated as of October 30, 2017 (as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with its terms prior to the date hereof, the “Credit Agreement”), among MEDNAX, INC., a Florida corporation
May 6, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
May 6, 2020	EX-99.1	North American Partners in Anesthesia (NAPA) Acquires American Anesthesiology From MEDNAX, Inc., to Create One of the Most Comprehensive Anesthesia, Pain Management, and Perioperative Care Companies in the U.S. EX-99.1 Exhibit 99.1 North American Partners in Anesthesia (NAPA) Acquires American Anesthesiology From MEDNAX, Inc., to Create One of the Most Comprehensive Anesthesia, Pain Management, and Perioperative Care Companies in the U.S. Melville, NY and Fort Lauderdale, FL — May 6, 2020 — North American Partners in Anesthesia (NAPA) and MEDNAX, Inc. (NYSE: MD) today jointly announced the completion of
April 28, 2020	EX-10.28	First Amendment to Employment Agreement, effective April 1, 2020, by and between MEDNAX Services, Inc. and John C. Pepia.* EX-10.28 Exhibit 10.28 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and JOHN C. PEPIA (“Employee”), effective as of April 1, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer and Employee are the parties to that certain Employment Agree
April 28, 2020	EX-10.26	First Amendment to Amended and Restated Employment Agreement, effective April 1, 2020, by and between MEDNAX Services, Inc. and Dominic J. Andreano.* EX-10.26 Exhibit 10.26 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and DOMINIC J. ANDREANO (“Employee”), effective as of April 1, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer and Employee
April 28, 2020	EX-10.25	Amended and Restated Employment Agreement, dated February 13, 2020, by and between MEDNAX Services, Inc. and Dominic J. Andreano.* EX-10.25 Exhibit 10.25 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”) and Dominic J. Andreano (“Employee”) effective as of February 13, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’s Business” as
April 28, 2020	EX-10.23	Amended and Restated Employment Agreement, dated February 13, 2020, by and between Mednax Services, Inc. and Stephen D. Farber (incorporated by reference to Exhibit 10.23 to Mednax’s Annual Report on Form 10-K/A for the year ended December 31, 2019, filed on April 28, 2020).* EX-10.23 Exhibit 10.23 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and STEPHEN D. FARBER (“Employee”), effective as of February 13, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer is presently engaged in “Employer’s Business” as
April 28, 2020	10-K/A	Annual Report - FORM 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001
April 28, 2020	EX-10.24	First Amendment to Amended and Restated Employment Agreement, effective April 1, 2020, by and between Mednax Services, Inc. and Stephen D. Farber. (incorporated by reference to Exhibit 10.24 to Mednax’s Annual Report on Form 10-K/A for the year ended December 31, 2019, filed on April 28, 2020).* EX-10.24 Exhibit 10.24 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”), and STEPHEN D. FARBER (“Employee”), effective as of April 1, 2020 (the “Effective Date”). RECITALS WHEREAS, Employer and Employee ar
April 7, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 7, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)
March 25, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 25, 2020 MEDNAX, INC. (Exact Name of Registrant as Specified in Its Charter) Florida 001-12111 26-3667538 (State or Other Jurisdiction of Incorporation) (Commission File Number)

MD / Pediatrix Medical Group, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings